Hereditary hemorrhagic telangiectasia · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Tamoxifen monotherapy Variant #06 | — | R 410 | 28d | ~7.2 mo | ~13.5 mo | ~8 | ~R 3 279 PFS proxy · indirect | 10 |
Pomalidomide monotherapy N/A - secondary systemic drug | — | R 0 | 28d | ~2.7 mo | — | ~3 | ~R 0 PFS proxy · indirect | 1 |
Tranexamic acid monotherapy Partial | — | — | — | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
4 of 4 regimens shown